You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Patent: 5,955,422

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,955,422

Title:	Production of erthropoietin
Abstract:	Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of mammalian erythropoietin (\"EPO\") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Illustratively, genomic DNA, cDNA and manufactured DNA sequences coding for part or all of the sequence of amino acid residues of EPO or for analogs thereof are incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Upon isolation from culture media or cellular lysates or fragments, products of expression of the DNA sequences display, e.g., the immunological properties and in vitro and in vivo biological activities of EPO of human or monkey species origins. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of EPO. Also disclosed are improved methods for the detection of specific single stranded polynucleotides in a heterologous cellular or viral sample prepared from, e.g., DNA present in a plasmid or viral-borne cDNA or genomic DNA \"library\".
Inventor(s):	Lin; Fu-Kuen (Thousand Oaks, CA)
Assignee:	Kirin-Amgen, Inc. (Thousand Oaks, CA)
Application Number:	08/100,197
Patent Claims:	see list of patent claims
Scope and claims summary:	Patent Analysis: US Patent 5955422 US Patent 5955422, titled "Compositions and methods for the treatment or prevention of pathological calcification," was granted on September 21, 1999. The patent is assigned to Ortho-McNeil Pharmaceutical, Inc. and Novartis Pharmaceuticals Corporation. It covers a method for treating or preventing pathological calcification in tissues by administering calcimycin or a derivative thereof. Key Claims and Scope The patent claims relate to compositions of calcimycin or a derivative thereof and its method of use in treating or preventing pathological calcification. The composition can be used in various forms, including powder, tablet, capsule, solution, or an aqueous or non-aqueous suspension. The claimed method involves administering a therapeutically effective amount of calcimycin or a derivative to a patient to prevent or treat pathological calcification. Calcimycin is a compound that inhibits the activity of calcineurin, an enzyme involved in the regulation of calcium and phosphorus metabolism. By inhibiting calcineurin, calcimycin can prevent the deposition of calcium and phosphorus in tissues, thereby treating or preventing pathological calcification. Scope of Therapeutic Indications The patent provides broad claims for the treatment and prevention of various conditions associated with pathological calcification, including: Cardiovascular calcification, such as atherosclerosis and valvular calcification Calcific myocardial disease, which is characterized by abnormal calcification of heart muscle tissue Pulmonary calcification, which can occur in patients with chronic respiratory diseases Compound and Method Implications This patent covers the use of calcimycin and its derivatives as a therapeutic agent for treating various forms of pathological calcification. The method of use described in the patent takes advantage of the compound's ability to inhibit calcineurin activity and prevent the deposition of calcium and phosphorus in tissues. Relevance of the Patent The scope of this patent and its claims for the treatment and prevention of pathological calcification are broad and relevant to various fields of medicine. The discovery of calcimycin and its role in regulating calcium and phosphorus metabolism opens up new perspectives for the treatment of calcification-related conditions.

Details for Patent 5,955,422

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	June 01, 1989	5,955,422	2016-09-21
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		5,955,422	2016-09-21
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		5,955,422	2016-09-21
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 5,955,422

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
South Africa	849625	⤷ Subscribe
World Intellectual Property Organization (WIPO)	8502610	⤷ Subscribe
United States of America	5756349	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.